Global Scientific Development in Advanced Cancer Therapies

This section provides educational information on emerging and advanced cancer therapies globally. Please refer to our homepage for services currently offered by SunAct.

Therapies

What is CAR T - cell Therapy?

CAR T (Chimeric Antigen Receptor T ‐ cell) therapy is a revolutionary cancer treatment that uses a patient’s own immune cells or donor cells to fight cancer.

How does CAR T - cell Therapy work?

  1. Collection: T ‐ cells are collected either from the patient’s blood through leukapheresis (Autologous CAR T) or sourced from a healthy donor (Allogeneic CAR T).
  2. Modification: The collected T ‐ cells are genetically engineered in a laboratory to express Chimeric Antigen Receptors (CARs) on their surface, enhancing their ability to target cancer cells.
  3. Expansion: The modified T ‐ cells are expanded in number to increase their effectiveness. In Autologous CAR T, this occurs using the patient’s own cells, while in Allogeneic CAR T, pre-manufactured donor cells are expanded.
  4. Infusion: The CAR T ‐ cells are infused into the patient’s bloodstream. For Autologous CAR T, this occurs after the patient undergoes conditioning therapy, while Allogeneic CAR T may be available for immediate infusion.
  5. Targeting Cancer: These engineered CAR T ‐ cells recognize and attack cancer cells throughout the body, helping eliminate tumors and improve patient outcomes.

Autologous CAR T - cell Therapy

  1. Source: Uses the patient’s own T ‐ cells
  2. Availability; Requires weeks to modify and expand cells
  3. Risk of Rejection: Lower risk (cells from self)
  4. Cost: Higher due to personalization
  5. Suitability: Best for patients who can wait
  6. Procedure: Cells collected from the patient, modified, expanded, and reinfused
  7. Process: Requires patient-specific T ‐ cell collection, genetic modification, and expansion before infusion

Allogeneic CAR T - cell Therapy

  1. Source: Uses donor T-cells (off-the-shelf)
  2. Availability: Readily available, faster treatment
  3. Risk of Rejection: Higher risk (cells from donor)
  4. Cost: Potentially lower due to mass production
  5. Suitability: Ideal for urgent cases or patients with weak immune systems
  6. Procedure: Pre-prepared donor cells infused directly into the patient
  7. Process: Donor-derived CAR-T cells are pre-manufactured and ready for immediate infusion

Benefits

Personalized Treatment : Uses the patient’s own cells, reducing the risk of rejection.

Targeted Action : Specifically designed to attack cancer cells.

Potential for Long-Term Remission : Some patients experience prolonged remission after treatment.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male